Melan-A Antibody (A103): sc-20032

Melan-A Antibody (A103) is an IgG₁ κ mouse monoclonal Melan-A antibody (also designated MART-1 antibody or MLANA antibody) that detects the Melan-A protein of mouse, rat and human origin by WB, IP, IF, IHC(P) and FCM. Melan-A Antibody (A103) is available as both the non-conjugated anti-Melan-A antibody form, as well as multiple conjugated forms of anti-Melan-A antibody, including agarose, HRP, PE, FITC and multiple Alexa Fluor^® conjugates. Melanoma-associated antigens recognized by cytotoxic T lymphocytes (CTL) have been grouped into three categories: melanocyte differentiation antigens, cancer/testis-specific antigens and mutated or aberrantly expressed antigens. Many of these antigens consist of peptides that are presented to T cells by HLA molecules; they represent potential targets for cancer immunotherapy. Melan-A (also designated MART-1) is a melanocyte differentiation antigen that is specific to melanomas, melanocyte cell lines and retina. Melan-A peptide is recognized by most HLA-A2-restricted tumor-specific tumor-infiltrating lymphocytes in patients with melanoma. Antimelanoma cytotoxic T lymphocytes can be generated with a Melan-A peptide, implicating Melan-A as a potential candidate for antigen-specific immunotherapy in melanoma patients.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

References:

1. Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells.  |  Vignard, V., et al. 2005. J Immunol. 175: 4797-805. PMID: 16177129
2. Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity.  |  Colombetti, S., et al. 2006. J Immunol. 176: 6560-7. PMID: 16709813
3. Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide.  |  Appay, V., et al. 2006. Eur J Immunol. 36: 1805-14. PMID: 16761313
4. Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas.  |  Chen, YT., et al. 1996. Proc Natl Acad Sci U S A. 93: 5915-9. PMID: 8650193
5. Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1.  |  Kawakami, Y., et al. 1997. J Immunol Methods. 202: 13-25. PMID: 9075767
6. Tumor antigens recognized by T lymphocytes.  |  Van den Eynde, BJ. and Boon, T. 1997. Int J Clin Lab Res. 27: 81-6. PMID: 9266277
7. Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35).  |  Loftus, DJ., et al. 1998. Cancer Res. 58: 2433-9. PMID: 9622085
8. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.  |  Busam, KJ., et al. 1998. Am J Surg Pathol. 22: 976-82. PMID: 9706977
9. Melanoma-associated antigens recognized by cytotoxic T lymphocytes.  |  Kirkin, AF., et al. 1998. APMIS. 106: 665-79. PMID: 9740504

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Melan-A Antibody (A103) has 38 citations in a variety of scientific publications.

Primary antibodies like Anti-Melan-A Antibody (A103) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Melan-A Antibody (A103) Specifications

Alternate Product Name

Melan-A

Product Clone Name

A103

Classification

Primary Antibody

Clonality

Monoclonal Antibody

Antibody Isotype

IgG₁ kappa light chain

Amino Acids

Epitope Target

Melan-A

Epitope Species

human

Product Reactivity/Detection

Melan-A

Species Reactivity/Detection

mouse, rat, human

Additional Mammalian Reactivity

N/A

Additional Non-Mammalian Reactivity

N/A

Applications

WB, IP, IF, IHC(P), FCM

Vialing Information

Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations

38 citations in various scientific publications

Recommended Secondary Detection Reagents

Mouse IgG Kappa Light Chain Binding Proteins

• m-IgGκ BP-HRP: sc-516102 (Mouse IgGκ light chain binding protein conjugated to horseradish peroxidase)
• m-IgGκ BP-B: sc-516142 (Mouse IgGκ light chain binding protein conjugated to biotin)
• m-IgGκ BP-FITC: sc-516140 (Mouse IgGκ light chain binding protein conjugated to fluorescein isothiocyanate)
• m-IgGκ BP-PE: sc-516141 (Mouse IgGκ light chain binding protein conjugated to phycoerythrin)
• m-IgGκ BP-CFL 488: sc-516176 (Mouse IgGκ light chain binding protein conjugated to CruzFluor™ 488)
• m-IgGκ BP-CFL 555: sc-516177 (Mouse IgGκ light chain binding protein conjugated to CruzFluor™ 555)
• m-IgGκ BP-CFL 594: sc-516178 (Mouse IgGκ light chain binding protein conjugated to CruzFluor™ 594)
• m-IgGκ BP-CFL 647: sc-516179 (Mouse IgGκ light chain binding protein conjugated to CruzFluor™ 647)
• m-IgGκ BP-CFL 680: sc-516180 (Mouse IgGκ light chain binding protein conjugated to CruzFluor™ 680)
• m-IgGκ BP-CFL 790: sc-516181 (Mouse IgGκ light chain binding protein conjugated to CruzFluor™ 790)

Available Conjugates/Forms

AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin